PT-141
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
On-demand central desire and arousal support: men usually look for 12-24 hours of stronger sexual interest and erection initiation, while women may feel easier arousal and sensitivity for up to 72 hours.
The useful dose window is narrow enough to respect: nausea affects about 40% of users at 1.75 mg, systolic blood pressure can rise transiently by about 6-8 mmHg, and men pushing 2 mg or more risk erections lasting beyond the 4-hour emergency threshold.
On-demand central desire and arousal support: men usually look for 12-24 hours of stronger sexual interest and erection initiation, while women may feel easier arousal and sensitivity for up to 72 hours. The best fit is desire restoration when PDE5 inhibitors, testosterone tuning, or GLP-1 medication changes have not fixed the central libido signal.
Dose-dependent nausea is the main limiter, especially near the 1.75 mg Vyleesi dose and above. Other ordinary-use issues are flushing, injection-site reactions, transient blood-pressure elevation, and occasional 24-hour post-dose low mood; the serious misuse scenario is priapism in men at 2 mg+ or when stacked aggressively with PDE5 inhibitors or injection erection drugs.
Strong value when it is used sparingly and precisely, because PT-141 offers a distinct brain-level desire mechanism rather than acting like a daily general sexual-performance supplement. Cost comparisons should separate approved medical products from unapproved peptide products.
High among responders, mixed at the population level. Responders describe a desire signal qualitatively different from PDE5 inhibitors, but clinical female HSDD trials show a modest placebo-adjusted response and the article documents a visible non-responder group that may not improve without AE-heavy dose escalation.
Do not combine with Melanotan II, high-dose same-day PDE5 inhibitors, nitrates, or casual full-dose erection stacks. PT-141 already occupies the melanocortin/erectogenic lane; redundant agonism adds nausea, flushing, blood-pressure strain, and priapism risk without a better desire signal.
Intro
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II.
It is the only FDA-approved non-hormonal, non-estrogen treatment for female sexual dysfunction, and the only sexual health compound that acts centrally — in the brain — to increase desire rather than peripherally on blood vessel dilation.
The compound traces back to melanocortin research in the 1980s, where a synthetic tanning-agent program unexpectedly revealed strong sexual-function effects. PT-141 was subsequently engineered to amplify libido-specific effects while minimizing the tanning mechanism, producing a selective MC3R/MC4R agonist that excludes the tanning-dominant MC1R pathway at therapeutic doses.
FDA approval came in 2019 as Vyleesi (1.75 mg SC, premenopausal women with HSDD), after Phase I through Phase III trials beginning in the early 2000s. The pivotal Phase III RECONNECT trial documented a 25% response rate for improved sexual desire versus 17% placebo — a modest absolute difference that nonetheless secured the first non-hormonal approval for female sexual dysfunction. The clinical development program ran male trials through Phase I only; the compound was not advanced through Phase II/III in men, leaving substantial male off-label use without clinical trial data beyond initial erectogenic dose-finding.
Community adoption preceded FDA approval, mostly around male libido, erectile dysfunction, and TRT-adjacent cases where testosterone correction did not restore desire. The 2019 approval validated the mechanism and expanded clinical availability, but it did not erase the distinction between approved medical use and unapproved peptide products. A later adoption wave emerged among GLP-1 users reporting medication-associated libido suppression. WADA clearance in 2025 expanded interest among tested athletes, but anti-doping status does not settle medical appropriateness or product quality.
Observed Effects
In men: Spontaneous erections emerging 30 minutes to several hours post-dose, typically sustained 12–24 hours.
Heightened awareness of partner attractiveness described qualitatively as feeling like 'a teenage boy in love' in multiple independent reports. Enhanced sensation and erection quality that community reporters consistently describe as superior to PDE5 inhibitor-facilitated erections. Reduced or eliminated refractory period. Phase I SC dose-finding (Diamond et al.) confirmed statistically significant erectogenic response at doses above 1.0 mg SC, including in men who had inadequate response to 100 mg sildenafil — demonstrating a mechanistically separate pathway, not just additive effect.
In women: Clinical trial data from Phase II dose-finding (Clayton et al. 2016, n=327): pooled 1.25 and 1.75 mg SC showed +0.7 satisfying sexual events/month versus +0.2 placebo (p=0.018), +3.6 versus +1.9 improvement in FSFI total score (p=0.0017), and significant reduction in FSDS-DAO distress scores (p=0.0014) — all three co-primary endpoints met. Women describe the effect as a 'mental shift first': heightened sexual interest without an obvious environmental trigger, easier arousal, improved sensitivity, full-body awareness, and an emotional connection component. Effect duration in women is notably longer than in men — up to 72 hours versus 12–24 hours at comparable doses.
Secondary and appetite-adjacent effects: Some users research PT-141 for appetite and visceral fat effects via melanocortin receptor involvement in metabolism — clinical evidence for this application does not exist and it is not a validated use case. MC1R activation at daily or high-frequency use can produce mild tanning; at on-demand dosing this is negligible versus Melanotan II. Oxytocin co-administration is reported anecdotally to add an emotional/bonding dimension that some users feel is absent from PT-141 alone.
Non-responders: A documented subset — approximately 25% in clinical trials and a visible proportion in community reports — reports no effect at standard doses. Some non-responders find that dose escalation to 2–2.5 mg produces response but with substantially increased adverse effects. A microdosing strategy (15–20 mcg five times daily, ~75–100 mcg/day total) has been reported by at least one experienced user to produce superior sustained libido versus single large doses.
Field Reports
The modal positive report is intermittent on-demand use with gradual onset of partner-focused desire, warmth, and physical interest that feels qualitatively different from baseline arousal.
Men often emphasize erection quality and refractory-period effects; women often emphasize sensitivity and desire.
The adverse pattern is dose-related: intense flushing, nausea, blood-pressure symptoms, and erections that last far beyond the intended window. First-dose overreach is a recurring failure mode. Non-response also occurs, and escalation can trade non-response for worse adverse effects.
Post-dose low mood around the next day is a minority but recurring report. Tolerance with frequent long-term use is also reported, which supports keeping PT-141 occasional rather than turning it into a daily libido supplement.
Community Consensus
PT-141 entered English-language community use before FDA approval, mostly around male libido, erectile dysfunction, and TRT-adjacent cases where testosterone correction did not restore desire.
The 2019 Vyleesi approval validated the central melanocortin mechanism but did not make all off-label or unapproved-product use equivalent to approved care.
A significant adoption wave emerged from GLP-1 users beginning in 2024, where semaglutide and tirzepatide users reported libido suppression and discussed PT-141 as a targeted restoration compound. The bodybuilding, TRT, biohacker, and female HSDD contexts each frame it differently, but the shared lesson is the same: useful when intermittent and dose-disciplined, much rougher when treated as a daily enhancement drug or stacked aggressively.
Risks & Monitoring
Nausea is the primary dose-limiting adverse effect and follows a clear dose-response pattern. Approximately 40% of subjects experience nausea at the FDA-approved 1.75 mg dose; rates are lower at 500 mcg–1 mg.
Onset is typically 30–90 minutes post-injection and resolves within 3–4 hours. First-time users at 2 mg or above frequently describe intense nausea as their dominant experience, which can overshadow the intended effects entirely. The 500 mcg community starting dose was partly calibrated to sit below the dose where nausea becomes the dominant experience. Pre-dosing with ondansetron (Zofran) 4 mg oral 30 minutes before injection is the evidence-informed community harm-reduction standard; some users use diphenhydramine (Benadryl) 30–45 minutes pre-dose to attenuate flushing via antihistamine mechanism.
Transient blood pressure elevation (+6–8 mmHg systolic) is observed 1–3 hours post-dose across all clinical trials and resolves without intervention. No clinically significant changes in ECGs, laboratory values, or physical examination findings were documented across studied dose ranges. Users with pre-existing hypertension or cardiovascular disease should treat this as a meaningful risk signal.
Priapism is a dose-dependent risk in men at doses of 2 mg and above. Multiple community first-person reports document erections lasting 6–15+ hours that did not resolve after the sexual encounter. This is not rare at 2 mg+ — it is an expected pharmacological consequence of strong MC3R/MC4R agonism without a physiological off switch at excessive doses. The 4-hour priapism threshold for emergency care applies. The 500 mcg–1 mg community standard was partly selected to avoid this risk zone.
Flushing (face redness, warmth) accompanies nausea at higher doses, typically resolving within 1–2 hours. Injection site reactions were documented in 13% of Phase III participants. A small subset of community reporters describe post-dose depression at approximately 24 hours — an idiosyncratic effect not well-characterized in clinical literature. At daily or high-frequency use, MC1R activation can produce mild skin hyperpigmentation (tanning).
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
PT-141 reliably produces a transient systolic BP rise in the article's clinical-trial summary. Users with uncontrolled hypertension, cardiovascular disease, chest symptoms, or unknown baseline BP need this gate before adding a compound that can raise pressure acutely.
A 1-3 hour post-dose check on the first few uses confirms whether the user's response stays near the expected +6-8 mmHg range. Larger or symptomatic excursions should trigger dose reduction or discontinuation.
The most important monitoring tool is not a lab: it is a per-use record of dose, onset, nausea/flushing, BP symptoms, mood at about 24 hours, and erection duration. The article's hard stop is an erection lasting more than 4 hours.
Useful when the presenting problem is male libido despite TRT or suspected low testosterone. PT-141 is not HPG-suppressive, so this is a differential-workup marker rather than a safety requirement for ordinary on-demand use.
Useful for men on TRT or with unexplained libido instability because high or crashed estradiol can mimic a desire/arousal deficit. It does not monitor a PT-141 toxicity pathway.
General baseline context only. The article does not identify a PT-141 hematologic risk signal, so CBC should not be treated as a required monitoring gate.
General baseline context only. The article reports no specific PT-141 metabolic or hepatic lab signal, so CMP is optional unless the user has comorbid disease or other medications that justify it.
Avoid With
Do not combine PT-141 with the following. Sorted highest-severity first.
Why:Direct receptor overlap — both compounds agonize MC3R and MC4R at therapeutic doses, with MT-2 additionally activating MC1R (tanning) and MC5R. Combining adds no sexual benefit while stacking nausea, flushing, and blood pressure elevation from two melanocortin agonists simultaneously.
What to do:This is the most common accidental overlap in the community. Users who run MT-2 loading protocols and add PT-141 on-demand for libido have no additive benefit on the libido mechanism and double their AE burden.
Why:PT-141 produces transient BP elevation (+6–8 mmHg systolic) while nitrates produce vasodilation and BP reduction. In patients on antihypertensive therapy, the BP effect of PT-141 is unpredictable and the interaction with nitrates (which are also PDE pathway-adjacent) can produce dangerous BP swings.
What to do:Nitrates are an absolute contraindication. Other antihypertensives require cardiovascular risk assessment before PT-141 use.
Why:Afamelanotide is a sustained-release implant for erythropoietic protoporphyria (MC1R agonist). Combining with PT-141 creates melanocortin receptor saturation across MC1R, MC3R, and MC4R simultaneously with one agent having multi-week duration.
What to do:Rare in the community but worth flagging for completeness — afamelanotide users should not add PT-141 while the implant is active.
Why:Additive erectogenic effect — PT-141 drives central arousal leading to erection initiation; PDE5 inhibitors prevent erection termination by blocking cGMP breakdown. The combination at standard full doses of both compounds substantially increases priapism risk, especially for men who are hyperresponders to either agent.
What to do:Use PT-141 with reduced PDE5i doses (tadalafil 5–10 mg, sildenafil 25–50 mg). Do not stack at full standard doses of both simultaneously.
Protocols By Goal
For female HSDD (FDA-approved indication): 1.75 mg SC, 45 minutes before anticipated sexual activity, as needed, max 8 doses/month.
Community adaptation: start at 1.0 mg for first 2–3 doses to establish tolerance, then escalate to 1.75 mg if well-tolerated. Track response across 2–3 uses before adjusting dose. The 72-hour effect window in women means timing can be less precise than in men — some women dose the morning before an evening encounter.
For male libido and erectile dysfunction: 500 mcg–1.75 mg SC, 30–90 minutes pre-activity. TRT-optimized men may need only 500 mcg–1 mg; men with deeper libido deficits often require 1.25–1.75 mg. Combination with low-dose tadalafil 5–10 mg daily or on-demand adds peripheral erection reliability to the central desire effect. Reduce tadalafil dose when combining — the additive erectogenic mechanism can lead to priapism at full standard doses of both compounds.
For men who fail PDE5 inhibitors: PT-141 alone at 1.0–2.0 mg SC, titrating from 1.0 mg. Phase I trial data confirms efficacy in men with inadequate response to 100 mg sildenafil. This is the compound's strongest clinical differentiation point. PDE5 inhibitor can be retained at reduced dose if desired for additive peripheral effect.
For GLP-1-associated libido decline: 500 mcg–1 mg on-demand, as needed. The mechanism matches the deficit — GLP-1 agonists can reduce central desire signaling, and PT-141 directly addresses this through MC4R stimulation. No dose adjustment specifically for GLP-1 co-administration documented; start conservatively and monitor for additive nausea given GLP-1's own nausea burden.
For couple use: Both partners can use PT-141 on the same occasion. Women dose 0.5–1.75 mg; men dose 500 mcg–1.5 mg. Stagger timing by 30–60 minutes if onset variability is a concern. The 12–72h effect window in women means a morning dose can cover an evening encounter, while men may prefer to dose closer to activity.
Dosing Details
Observed dose range: Community and clinical use generally centers on intermittent, on-demand exposure rather than daily supplementation.
The FDA-approved female HSDD product uses 1.75 mg SC with an 8-dose/month ceiling. Male off-label reports often discuss lower tolerance-test exposures through roughly the same on-demand range, with higher starts carrying more nausea, blood-pressure, and priapism risk.
Timing: Reported onset varies widely, from under an hour to several hours. First trials are commonly treated as calibration events rather than high-stakes plans, because nausea and onset timing are individual.
Routes: Subcutaneous injection is the studied and approved route. Nasal routes are reported but less predictable and should not be treated as equivalent to SC dosing.
Microdosing reports: Ultra-low repeated dosing has been described anecdotally, but it is not a validated protocol and should remain an experimental report rather than reader-facing instruction.
Nausea and adverse-effect management: Nausea, flushing, blood-pressure symptoms, and prolonged erections are dose-limiting signals. Full-dose PDE5 inhibitor or Trimix stacking, aggressive first doses, and frequent use move the risk profile away from casual libido support and toward medical-risk territory.
Stop conditions: Erection lasting more than 4 hours, symptomatic blood-pressure elevation, severe nausea, allergic reaction, or repeat post-dose mood crash should stop use and prompt medical care where appropriate.
Stacks & Alternatives
Complementary mechanisms — PT-141 handles central desire and arousal initiation; tadalafil handles peripheral erection reliability via PDE5 inhibition. Reduce tadalafil dose when combining; the additive erectogenic effect at full doses of both risks priapism. Used by TRT community and surgically-erectile-dysfunctional men. FrankTalk Trimix-using men confirm qualitatively harder erections when PT-141 precedes Trimix injection.
PT-141 can produce 'purely physical' arousal that some users feel lacks emotional/bonding dimension. Intranasal oxytocin (20–100 IU, 30–60 min pre-intercourse) rounds out the emotional connection component. Used by both sexes. Some GLP-1 users specifically note this combination. An experienced community educator recommends oxytocin alongside PT-141 in his published libido protocol, dosed at 2–3x weekly max.
PT-141 works better when testosterone levels are optimized. Community consensus is that testosterone provides the hormonal substrate; PT-141 provides the CNS desire signal. Men whose libido deficits persist despite well-tuned TRT use PT-141 as the next-step compound. The combination is mechanistically additive, not redundant. Optimizing testosterone first before adding PT-141 is the standard protocol order.
Same logic as tadalafil — central desire from PT-141 plus peripheral erection support from sildenafil. Reduce sildenafil dose when combining; standard doses of both carry priapism risk. For on-demand use (vs daily Cialis), the timing alignment of sildenafil with PT-141's onset window (both 30–60 min) is practical.
For men with surgical or severe vascular erectile dysfunction where PDE5 inhibitors are insufficient. PT-141 pre-dosed at least 2 hours before Trimix injection produces qualitatively harder erections than Trimix alone, with spontaneous arousal throughout the pre-Trimix window. The combination requires careful dose management to avoid prolonged erection.
Alternatives
Stack Cost
Moderate stack tax: PT-141 is non-hormonal and on-demand, but it consumes an acute sexual-function/CNS lane with real nausea, blood-pressure, priapism, interaction, and injection-timing constraints.
The desired effect is central MC3R/MC4R arousal signaling, and the article documents dose-dependent nausea, flushing, variable onset, 12-72 hour subjective effect windows, and occasional 24-hour post-dose low mood.
The clinical safety signal is not chronic lipid or liver injury; it is acute hemodynamics. The article repeatedly flags transient +6-8 mmHg systolic BP elevation and contraindication-level concern for uncontrolled hypertension or cardiovascular disease.
PT-141 stacks well with reduced-dose PDE5 inhibitors, but full-dose same-day PDE5i, Trimix-style erection drugs, nitrates, and redundant melanocortin agonists can escalate priapism, BP, nausea, or flushing risk.
The usual route is subcutaneous injection with simple reconstitution math, but unit conversion errors matter because 500 mcg, 1.75 mg, and 2 mg+ sit in very different tolerability and priapism zones.
The article describes a wide access split: unapproved peptide products versus supervised medical products, with quality confidence depending on oversight and identity assurance.
- ·Know baseline BP before first use; do not use during uncontrolled hypertension, acute cardiovascular symptoms, or unstable cardiac disease.
- ·Start at 500 mcg rather than copying the 1.75 mg Vyleesi dose or a 2 mg community protocol.
- ·Do not escalate above 1.75 mg without a clear failed-response pattern and tolerance history.
- ·Treat an erection lasting more than 4 hours as an emergency stop condition.
- ·If combining with tadalafil or sildenafil, use reduced PDE5i doses and avoid full-dose same-day stacking.
- ·BP cuff and first-use post-dose BP spot checks.
- ·Dose, onset, nausea, flushing, mood, and erection-duration log.
- ·Antiemetic or nausea plan for users trialing 1 mg+ doses.
- ·Clear emergency plan for priapism in men.
- ·Hormone workup only when the libido problem may be testosterone, estradiol, or TRT-management driven.
PT-141 is not hormonally suppressive and does not require PCT, but it is not beginner-casual because dose errors or aggressive stacking can produce intense nausea, symptomatic BP elevation, or priapism.
- ·Uncontrolled hypertension, cardiovascular disease, chest pain, or unexplained exertional symptoms.
- ·History of priapism or likely same-day full-dose PDE5 inhibitor or Trimix stacking.
- ·Cannot tolerate nausea or does not have a plan for first-dose adverse effects.
- ·Pregnant, trying to conceive without clinician input, or using PT-141 outside the studied HSDD context.
PT-141 is on-demand, short half-life, and non-suppressive. Stopping usually means skipping the next dose rather than tapering or recovering an axis.
- ·Loss of the acute libido/arousal effect.
- ·Possible disappointment or relationship planning friction if relied on for specific encounters.
- ·Need to reassess hormonal, vascular, medication, or psychological causes if non-response persists.
Start at 500 mcg, keep first trials away from high-pressure plans, and reduce or stop if the adverse-effect window dominates the desired effect.
Avoid 2 mg+ starts and full-dose erection stacks; treat 4 hours as an emergency-care threshold.
Repeat at a controlled dose/timing before escalating; evaluate hormonal or medication causes rather than treating PT-141 as a universal libido fix.
Keep use occasional, take breaks when response fades, and stop daily/high-frequency patterns unless supervised.
The article's consistent trial safety signal is transient BP elevation; unstable baseline cardiovascular status turns a modest acute effect into a higher-risk event.
PT-141 plus full-dose PDE5 inhibitors, Trimix, or 2 mg+ PT-141 moves the user toward the article's prolonged-erection failure mode.
The article treats pregnancy as contraindicated and notes limited reproductive data despite rapid washout and non-hormonal mechanism.
The article documents a minority recurring report around 24 hours post-dose; repetition turns an idiosyncratic signal into a stop condition.
Practical Setup
Product context: Approved bremelanotide, compounded products, and unapproved peptide products are not equivalent. Identity, sterility, concentration, storage, and measurement accuracy are central practical risks outside approved products.
Route and dose discipline: SC use is the studied route. Nasal use and improvised preparation have less predictable exposure. First use should be treated as a tolerability calibration, not a high-pressure event.
Drug interactions: Nitrate users and people with uncontrolled cardiovascular risk need clinician input because PT-141 can raise blood pressure transiently. Full-dose same-day PDE5 inhibitor or injection-erection stacking increases prolonged-erection risk.
Monitoring and adjustment: Track blood pressure symptoms, nausea severity, mood at roughly 24 hours, onset time, and erection duration. Lower exposure often preserves much of the desired effect with less nausea.
Stop conditions: Erection lasting more than 4 hours is a medical emergency. Severe nausea, symptomatic blood-pressure elevation, allergic reaction, or repeated post-dose depression should stop use.
Mechanism Deep Dive
MC3R and MC4R agonism — the desire pathway
PT-141 is a cyclic heptapeptide melanocortin receptor agonist derived from the Melanotan II (MT-II) sequence. Its cyclic structure confers resistance to proteolytic degradation compared to the linear α-MSH parent peptide. The compound agonizes melanocortin receptors 3 and 4 (MC3R and MC4R) as primary pharmacological targets and critically excludes significant MC2R activation. MC2R is the ACTH receptor — its stimulation would drive the hypothalamic-pituitary-adrenal axis, stimulating cortisol release. The selectivity for MC3R/MC4R over MC2R is safety-critical and mechanistically deliberate.
MC4R is densely expressed in the paraventricular nucleus (PVN) of the hypothalamus — the brain region where melanocortin signaling initiates the downstream cascade driving sexual arousal. MC4R activation in the PVN triggers dopaminergic and oxytocinergic signaling, producing subjective desire, heightened salience of sexual stimuli, and downstream physiological arousal. This is entirely different from peripheral vasodilatory mechanisms — PT-141 acts in the brain, not on penile vasculature.
Central vs peripheral distinction
The clinical significance of the central mechanism: PDE5 inhibitors (sildenafil, tadalafil) facilitate blood flow to genital tissue but do not address desire, motivation, or CNS arousal. Clinical trials in women with sexual arousal disorder demonstrated that PDE5 inhibitors fail to produce meaningful improvement in female sexual response precisely because the underlying disorder is one of desire and central arousal, not peripheral blood flow. PT-141's success in women — and in men who fail sildenafil — follows directly from this mechanistic distinction.
Pharmacokinetics
SC administration: Tmax approximately 1 hour. Half-life approximately 1.85–2.09 hours (Phase I intranasal data; SC half-life similar). Dose-proportional pharmacokinetics across the studied dose range. The community-reported effect duration of 12–72 hours significantly exceeds the pharmacokinetic half-life, suggesting receptor-mediated downstream signaling persistence after the peptide itself has cleared.
MC1R and tanning
At standard on-demand doses PT-141 produces minimal MC1R (melanocyte-stimulating receptor, tanning receptor) activation. With daily use or high-frequency dosing, MC1R stimulation accumulates and produces skin hyperpigmentation — less than Melanotan II at its effective dose, but present. The community distinguishes: 'PT-141 at once-weekly on-demand produces no meaningful tan; daily use over two weeks produces visible darkening.'
Loading phase
Some users report a receptor-saturation or sensitization effect with daily use for several days — subsequent on-demand doses produce faster onset (20–30 minutes) compared to first-use onset (1–2 hours). The precise mechanism is unknown but is hypothesized to involve MC4R upregulation, receptor trafficking changes, or altered downstream signaling kinetics in the PVN. This loading phase was described by experienced community educators based on user reports and is not yet characterized in clinical literature.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Statistically significant erectogenic response at doses above 1.0 mg SC, including in men who had inadequate response to 100 mg sildenafil
Phase I dose-finding only; no Phase II/III in men. Transfer to general male population is reasonable but limited by Phase I sample size.
+0.7 satisfying sexual events/month versus +0.2 placebo (p=0.018), +3.6 vs +1.9 FSFI total score improvement (p=0.0017)
Phase II RCT in women with diagnosed HSDD — does not generalize to healthy women seeking enhancement or postmenopausal women.
25% response rate for improved sexual desire versus 17% placebo in Phase III RECONNECT trial
FDA approval basis. The 8 percentage-point absolute difference over placebo reflects heterogeneity of HSDD; community responder rates may differ.
Nausea in approximately 40% of subjects at therapeutic doses; flushing 20%, injection site reactions 13%
Phase III clinical trial adverse event rates. Community reports at 500 mcg–1 mg suggest substantially lower nausea rates.
Transient blood pressure elevation (+6–8 mmHg systolic) observed 1–3 hours post-dose, resolving without intervention
Consistent finding across all clinical trials. Magnitude may differ in hypertensive populations — no data available.
Tmax approximately 1 hour after SC injection with dose-proportional pharmacokinetics
Phase I PK data. PK profile expected to be similar in women but not separately characterized.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.